questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Benzazépines
Benzodiazépines
Olanzapine
Olanzapine : Questions médicales fréquentes
Diagnostic
5
Troubles psychotiques
Diagnostic médical
Évaluation des symptômes
Traitement antipsychotique
Trouble bipolaire
Dépression
Critères de prescription
Antipsychotiques
Effets secondaires
Suivi clinique
Symptômes
5
Hallucinations
Troubles de l'humeur
Effets indésirables
Syndrome métabolique
Symptômes extrapyramidaux
Antipsychotiques
Stabilisation de l'humeur
Neurotransmetteurs
Surdose
Confusion mentale
Prévention
5
Prévention des rechutes
Suivi médical
Effets secondaires
Mode de vie sain
Éducation des patients
Adhésion au traitement
Gestion du stress
Techniques de relaxation
Groupes de soutien
Soutien émotionnel
Traitements
5
Administration orale
Formes pharmaceutiques
Posologie
Antipsychotiques
Polythérapie
Interactions médicamenteuses
Objectifs thérapeutiques
Qualité de vie
Surveillance thérapeutique
Évaluation des symptômes
Complications
5
Syndrome métabolique
Complications cardiovasculaires
Gestion des complications
Ajustement de dosage
Fonction hépatique
Tests de laboratoire
Risques à long terme
Santé mentale
Prévention des complications
Évaluation des risques
Facteurs de risque
5
Facteurs de risque
Antécédents médicaux
Antécédents familiaux
Troubles mentaux
Mode de vie
Efficacité du traitement
Interactions médicamenteuses
Effets secondaires
Évaluation des risques
Entretiens cliniques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Olanzapine : Questions médicales les plus fréquentes",
"headline": "Olanzapine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Olanzapine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-06",
"dateModified": "2026-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Olanzapine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Benzodiazépines",
"url": "https://questionsmedicales.fr/mesh/D001569",
"about": {
"@type": "MedicalCondition",
"name": "Benzodiazépines",
"code": {
"@type": "MedicalCode",
"code": "D001569",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Olanzapine",
"alternateName": "Olanzapine",
"code": {
"@type": "MedicalCode",
"code": "D000077152",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ying Jiang",
"url": "https://questionsmedicales.fr/author/Ying%20Jiang",
"affiliation": {
"@type": "Organization",
"name": "Alkermes, Inc., Waltham, MA, USA."
}
},
{
"@type": "Person",
"name": "David McDonnell",
"url": "https://questionsmedicales.fr/author/David%20McDonnell",
"affiliation": {
"@type": "Organization",
"name": "Alkermes Pharma Ireland Limited, Dublin, Ireland."
}
},
{
"@type": "Person",
"name": "Nuno F da Costa",
"url": "https://questionsmedicales.fr/author/Nuno%20F%20da%20Costa",
"affiliation": {
"@type": "Organization",
"name": "iMed.ULisboa-Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal."
}
},
{
"@type": "Person",
"name": "Ana I Fernandes",
"url": "https://questionsmedicales.fr/author/Ana%20I%20Fernandes",
"affiliation": {
"@type": "Organization",
"name": "CiiEM-Interdisciplinary Research Center Egas Moniz, Instituto Universitário Egas Moniz, Monte de Caparica, 2829-511 Caparica, Portugal."
}
},
{
"@type": "Person",
"name": "João F Pinto",
"url": "https://questionsmedicales.fr/author/Jo%C3%A3o%20F%20Pinto",
"affiliation": {
"@type": "Organization",
"name": "iMed.ULisboa-Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A Case of Olanzapine-Induced Cutaneous Eruption.",
"datePublished": "2023-10-01",
"url": "https://questionsmedicales.fr/article/37777823",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.12659/AJCR.941379"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of olanzapine and lithium carbonate antipsychotic agents on dopamine oxidation.",
"datePublished": "2023-07-10",
"url": "https://questionsmedicales.fr/article/37350329",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1039/d3an00270e"
}
},
{
"@type": "ScholarlyArticle",
"name": "CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.",
"datePublished": "2023-10-28",
"url": "https://questionsmedicales.fr/article/37898643",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-45752-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Olanzapine for Non-Chemotherapy Related Nausea and Emesis in Patients with a Palliative Care Consult.",
"datePublished": "2023-06-20",
"url": "https://questionsmedicales.fr/article/37348739",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jpainsymman.2023.06.019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders.",
"datePublished": "2024-07-03",
"url": "https://questionsmedicales.fr/article/38958149",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD013425.pub2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Benzazépines",
"item": "https://questionsmedicales.fr/mesh/D001552"
},
{
"@type": "ListItem",
"position": 6,
"name": "Benzodiazépines",
"item": "https://questionsmedicales.fr/mesh/D001569"
},
{
"@type": "ListItem",
"position": 7,
"name": "Olanzapine",
"item": "https://questionsmedicales.fr/mesh/D000077152"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Olanzapine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Olanzapine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Olanzapine",
"description": "Comment diagnostiquer un trouble psychotique ?\nQuels tests sont utilisés pour évaluer l'efficacité de l'olanzapine ?\nL'olanzapine est-elle utilisée pour d'autres troubles ?\nQuels critères sont utilisés pour prescrire l'olanzapine ?\nComment évaluer les effets secondaires de l'olanzapine ?",
"url": "https://questionsmedicales.fr/mesh/D000077152#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Olanzapine",
"description": "Quels symptômes l'olanzapine traite-t-elle ?\nQuels sont les effets secondaires courants de l'olanzapine ?\nL'olanzapine peut-elle provoquer des symptômes extrapyramidaux ?\nComment l'olanzapine affecte-t-elle l'humeur ?\nQuels signes indiquent une surdose d'olanzapine ?",
"url": "https://questionsmedicales.fr/mesh/D000077152#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Olanzapine",
"description": "Comment prévenir les rechutes chez les patients sous olanzapine ?\nQuels conseils donner pour éviter les effets secondaires ?\nL'éducation des patients est-elle importante ?\nComment gérer le stress pour les patients sous olanzapine ?\nLes groupes de soutien sont-ils bénéfiques ?",
"url": "https://questionsmedicales.fr/mesh/D000077152#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Olanzapine",
"description": "Comment l'olanzapine est-elle administrée ?\nQuelle est la posologie standard de l'olanzapine ?\nL'olanzapine peut-elle être combinée avec d'autres médicaments ?\nQuels sont les objectifs du traitement avec l'olanzapine ?\nComment surveiller l'efficacité de l'olanzapine ?",
"url": "https://questionsmedicales.fr/mesh/D000077152#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Olanzapine",
"description": "Quelles complications peuvent survenir avec l'olanzapine ?\nComment gérer les complications liées à l'olanzapine ?\nL'olanzapine peut-elle affecter la fonction hépatique ?\nQuels sont les risques à long terme de l'olanzapine ?\nComment prévenir les complications graves ?",
"url": "https://questionsmedicales.fr/mesh/D000077152#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Olanzapine",
"description": "Quels facteurs augmentent le risque d'effets secondaires ?\nLes antécédents familiaux influencent-ils le traitement ?\nLe mode de vie affecte-t-il l'efficacité de l'olanzapine ?\nLes interactions médicamenteuses sont-elles un risque ?\nComment évaluer les facteurs de risque chez un patient ?",
"url": "https://questionsmedicales.fr/mesh/D000077152#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un trouble psychotique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation clinique et des critères DSM-5."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité de l'olanzapine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des échelles d'évaluation des symptômes et des entretiens cliniques sont utilisés."
}
},
{
"@type": "Question",
"name": "L'olanzapine est-elle utilisée pour d'autres troubles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est également utilisée pour le trouble bipolaire et la dépression résistante."
}
},
{
"@type": "Question",
"name": "Quels critères sont utilisés pour prescrire l'olanzapine ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent la gravité des symptômes et la réponse aux traitements antérieurs."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets secondaires de l'olanzapine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des questionnaires et des suivis cliniques réguliers."
}
},
{
"@type": "Question",
"name": "Quels symptômes l'olanzapine traite-t-elle ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle traite les hallucinations, les délires et les troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants de l'olanzapine ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets incluent la prise de poids, la somnolence et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "L'olanzapine peut-elle provoquer des symptômes extrapyramidaux ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, bien que moins fréquents que d'autres antipsychotiques, ils peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment l'olanzapine affecte-t-elle l'humeur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle stabilise l'humeur en modulant les neurotransmetteurs dans le cerveau."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une surdose d'olanzapine ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent confusion, somnolence excessive et troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Comment prévenir les rechutes chez les patients sous olanzapine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut un suivi régulier et l'adhésion au traitement prescrit."
}
},
{
"@type": "Question",
"name": "Quels conseils donner pour éviter les effets secondaires ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain, surveiller le poids et consulter régulièrement un médecin."
}
},
{
"@type": "Question",
"name": "L'éducation des patients est-elle importante ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation aide les patients à comprendre leur traitement et à signaler les problèmes."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pour les patients sous olanzapine ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de gestion du stress comme la méditation et l'exercice sont recommandées."
}
},
{
"@type": "Question",
"name": "Les groupes de soutien sont-ils bénéfiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils offrent un soutien émotionnel et des conseils pratiques aux patients et familles."
}
},
{
"@type": "Question",
"name": "Comment l'olanzapine est-elle administrée ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est généralement administrée par voie orale sous forme de comprimés ou de solution."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie standard de l'olanzapine ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie varie de 5 à 20 mg par jour, selon la condition traitée."
}
},
{
"@type": "Question",
"name": "L'olanzapine peut-elle être combinée avec d'autres médicaments ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être combinée avec d'autres traitements, mais sous surveillance médicale."
}
},
{
"@type": "Question",
"name": "Quels sont les objectifs du traitement avec l'olanzapine ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les objectifs incluent la réduction des symptômes et l'amélioration de la qualité de vie."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité de l'olanzapine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est surveillée par des évaluations régulières des symptômes et des effets."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'olanzapine ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent le syndrome métabolique et des troubles cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'olanzapine ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut des ajustements de dosage et un suivi médical régulier."
}
},
{
"@type": "Question",
"name": "L'olanzapine peut-elle affecter la fonction hépatique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests de la fonction hépatique sont recommandés pour surveiller les effets."
}
},
{
"@type": "Question",
"name": "Quels sont les risques à long terme de l'olanzapine ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des troubles métaboliques et des effets sur la santé mentale."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications graves ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier et une évaluation des facteurs de risque sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, le poids, et les antécédents médicaux peuvent augmenter le risque d'effets."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le traitement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de troubles mentaux peuvent influencer le choix du traitement."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il l'efficacité de l'olanzapine ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut améliorer l'efficacité et réduire les effets secondaires."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions peuvent augmenter les effets secondaires ou diminuer l'efficacité."
}
},
{
"@type": "Question",
"name": "Comment évaluer les facteurs de risque chez un patient ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des entretiens cliniques et des questionnaires standardisés."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 26/03/2026
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Alkermes, Inc., Waltham, MA, USA.
Publications dans "Olanzapine" :
3 publications dans cette catégorie
Affiliations :
Alkermes Pharma Ireland Limited, Dublin, Ireland.
Publications dans "Olanzapine" :
3 publications dans cette catégorie
Affiliations :
iMed.ULisboa-Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
Publications dans "Olanzapine" :
3 publications dans cette catégorie
Affiliations :
CiiEM-Interdisciplinary Research Center Egas Moniz, Instituto Universitário Egas Moniz, Monte de Caparica, 2829-511 Caparica, Portugal.
Publications dans "Olanzapine" :
3 publications dans cette catégorie
Affiliations :
iMed.ULisboa-Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
Alkermes, Inc., Waltham, MA, USA. Christine.Graham@alkermes.com.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
Centre for Addiction and Mental Health, Toronto, ON, Canada; Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada; Department of Pharmacology, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Banting & Best Diabetes Centre, Toronto, ON, Canada. Electronic address: margaret.hahn@camh.ca.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Targeted Drug Delivery Research Center, Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. hosseinzadehh@mums.ac.ir.
Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. hosseinzadehh@mums.ac.ir.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.
Publications dans "Olanzapine" :
2 publications dans cette catégorie
Affiliations :
Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.
Publications dans "Olanzapine" :
BACKGROUND Different medication classes have been implicated in cutaneous eruptions that may lead to significant morbidity and mortality. In drug reaction with eosinophilia and systemic symptoms (DRES...
Olanzapine (OLZ) and lithium carbonate (Li...
Olanzapine is a commonly prescribed atypical antipsychotic agent for treatment of patients with schizophrenia and bipolar disorders. Previous in vitro studies using human liver microsomes identified C...
Current palliative care guidelines lack a specific treatment algorithm for nausea and emesis. Olanzapine is an atypical antipsychotic with antiemetic activity that's recommended in the guidelines for ...
To describe the safety and efficacy of olanzapine for nausea and emesis in the palliative care domain, excluding patients actively undergoing chemotherapy or radiation....
This retrospective chart review encompassed hospitalized adult patients from six hospitals across a large health system admitted from August 2020 through August 2021, with a palliative care consult, a...
A total of 78 patients were included in the study. Olanzapine decreased the number of doses required of antiemetic medications, the median doses of antiemetic medications pre-olanzapine was 1.6 (IQR 0...
This retrospective review demonstrated benefit to utilizing olanzapine for nausea and emesis in palliative care patients and should be considered to aid in symptom management....
Schizophrenia is often a severe and disabling psychiatric disorder. Antipsychotics remain the mainstay of psychotropic treatment for people with psychosis. In limited resource and humanitarian context...
To assess the clinical benefits and harms of haloperidol compared to olanzapine for people with schizophrenia and schizophrenia-spectrum disorders....
We searched the Cochrane Schizophrenia study-based register of trials, which is based on monthly searches of CENTRAL, CINAHL, ClinicalTrials.gov, Embase, ISRCTN, MEDLINE, PsycINFO, PubMed and WHO ICTR...
Randomised clinical trials comparing haloperidol with olanzapine for people with schizophrenia and schizophrenia-spectrum disorders. Our main outcomes of interest were clinically important change in g...
We independently evaluated and extracted data. For dichotomous outcomes, we calculated risk ratios (RR) and their 95% confidence intervals (CI) and the number needed to treat for an additional benefic...
We included 68 studies randomising 9132 participants. We are very uncertain whether there is a difference between haloperidol and olanzapine in clinically important change in global state (RR 0.84, 95...
Overall, the certainty of the evidence was low to very low for the main outcomes in this review, making it difficult to draw reliable conclusions. We are very uncertain whether there is a difference b...
The role of olanzapine has not been adequately evaluated in moderately emetogenic chemotherapy (MEC) regimens with or without neurokinin-1 receptor antagonists....
To evaluate whether addition of olanzapine to an MEC regimen reduces nausea, vomiting, and use of nausea rescue medications among patients with solid malignant tumors....
This multicenter, open-label phase 3 randomized clinical trial included patients aged 18 years or older with solid malignant tumors who were receiving oxaliplatin-, carboplatin-, or irinotecan-based c...
Patients were randomized 1:1 to dexamethasone, aprepitant, and palonosetron with olanzapine (experimental group) or without olanzapine (observation group). The experimental group received 10 mg of ola...
The primary end point was complete response (CR), defined as the proportion of patients with no vomiting, no significant nausea (scored as <5 on a visual analog scale of 1 to 100), and no use of rescu...
A total of 560 patients (259 [64%] male; median age, 51 years [range, 19-80 years]) were randomized. The analysis included 544 patients with evaluable data (274 assigned to olanzapine and 270 to obser...
In this randomized clinical trial, the addition of olanzapine significantly improved CR rates as well as nausea and vomiting prevention rates in chemotherapy-naive patients who were receiving MEC regi...
Clinical Trials Registry-India (CTRI) Identifier: CTRI/2018/12/016643....
Induced pluripotent stem cell (iPSC) based neuronal differentiation is valuable for studying neuropsychiatric disorders and pharmacological mechanisms at the cellular level. We aimed to examine the ef...
Proliferation and neurite outgrowth were measured by live cell imaging, and gene expression levels related to neuronal identity were analyzed by RT-QPCR and immunocytochemistry during differentiation ...
Antipsychotics did not modify the growth properties of NPCs after 3 days of treatment. However, the characteristics of neurite outgrowth changed significantly in response to haloperidol and olanzapine...
Altogether, antipsychotic medications promoted neurogenesis in vitro by influencing neurite outgrowth rather than changing cell survival or gene expression. This study provides insights into the effec...
Cognitive impairments are a hallmark symptom of schizophrenia (SCZ). Phosphatidylethanolamine (PE) is the second most abundant phospholipid in mammalian cells, yet its role in cognitive deficits remai...
Twenty-five female DNFE SCZ patients were treated with olanzapine for four weeks, and cognitive function was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBAN...
Significant improvements in immediate and delayed memory domains were observed post-treatment. We identified nine differential LysoPE species after olanzapine monotherapy, with increased concentration...
This study offers preliminary evidence for the involvement of LysoPE in cognitive improvements observed in drug-naïve first-episode SCZ patients after olanzapine treatment....
Postoperative nausea or vomiting occurs in up to 40% in patients with multiple risk factors, despite prophylaxis. Olanzapine is an antipsychotic drug that is used to prevent nausea and vomiting in pal...
Drugs have actions that may be classified as therapeutic effects and side effects; side effects are actions that do not contribute to therapeutic benefit. Some side effects are neutral; others, experi...